transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2019-6-5-16-23transmed-517Research ArticleСЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯCARDIOVASCULAR MEDICINEФенотипическая характеристика мезенхимных клеток сердца, полученных от пациентов с тетрадой Фалло и дефектом межжелудочковой перегородкиCharacterization of mesenchymal heart cells obtained from patients with tetralogy of Fallot and ventricular septal defectКозыревИ. А.KozyrevI. A.

Козырев Иван Александрович, врач — сердечно-сосудистый хирург отделения детской сердечно-сосудистой хирургии

Kozyrev Ivan A., Cardiac Surgeon Department of Pediatric Cardiac Surgery

dr.kozyrev@gmail.comГоловкинА. С.GolovkinA. S.

Головкин Алексей Сергеевич, д.м.н., ведущий научный сотрудник Института молекулярной биологии и генетики

Golovkin Alexey S., PhD, Dr. Sc., Senior Researcher, Institute of Molecular Biology and Genetics

ИгнатьеваЕ. С.IgnatievaE. S.

Игнатьева Елена Сергеевна, младший научный сотрудник Института молекулярной биологии и генетики

Ignatieva Elena S., Senior Researcher, Institute of Molecular Biology and Genetics

ДокшинП. М.DokshinP. M.

Докшин Павел Михайлович, младший научный сотрудник Института молекулярной биологии и генетики

Dokshin Pavel M., Junior Researcher, Institute of Molecular Biology and Genetics

ГреховЕ. В.GrekhovE. V.

Грехов Евгений Викторович, к.м.н., старший научный сотрудник, руководитель научно-исследовательской группы детской кардиохирургии

Grekhov Evgeny V., PhD, Head of the Research Group for Pediatric Cardiac Surgery

ГордеевМ. Л.GordeevM. L.

Гордеев Михаил Леонидович, д.м.н., заведующий НИО кардиоторакальной хирургии

Gordeev Mikhail L., PhD, Dr. Sc., Head of the Research Department of Cardiothoracic Surgery

ПервунинаТ. М.PervuninaT. M.

Первунина Татьяна Михайловна, к.м.н., директор Института перинатологии и педиатрии

Pervunina Tatiana M., PhD, Head of the Institute of Perinatology and Pediatrics

КостареваА. А.KostarevaA A.

Костарева Анна Александровна, к.м.н., директор Института молекулярной биологии и генетики

Kostareva Anna A., PhD, Head of Institute of Molecular Biology and Genetics

МалашичеваА. Б.MalashichevaA. B.

Малашичева Анна Борисовна, к.б.н., заведующий НИЛ молекулярной кардиологии Института молекулярной биологии и генетики 

ведущий научный сотрудник, заведующий лабораторией регенеративной биомедицины

Malashicheva Anna B., PhD, Head Research Laboratory of Molecular Cardiology, Institute of Molecular Biology and Genetics

Leading Researcher, Head of laboratory of Regenerative Biomedicine

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наукРоссияAlmazov National Medical Research Centre; Institute of Cytology of the Russian Academy of ScienceRussian Federation201917112019651623Copyright © Козырев И.А., Головкин А.С., Игнатьева Е.С., Докшин П.М., Грехов Е.В., Гордеев М.Л., Первунина Т.М., Костарева А.А., Малашичева А.Б., 20192019Козырев И.А., Головкин А.С., Игнатьева Е.С., Докшин П.М., Грехов Е.В., Гордеев М.Л., Первунина Т.М., Костарева А.А., Малашичева А.Б.Kozyrev I.A., Golovkin A.S., Ignatieva E.S., Dokshin P.M., Grekhov E.V., Gordeev M.L., Pervunina T.M., Kostareva A.A., Malashicheva A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/517Цель

Цель. Фенотипический анализ мезенхимных клеток сердца от пациентов с дефектом межжелудочковой перегородки и тетрадой Фалло.

Методы

Методы. В исследование включены мезенхимные клетки сердца от 8 пациентов с дефектом межжелудочковой перегородки и от 18 пациентов с тетрадой Фалло, которым выполнена радикальная коррекция порока. С помощью метода проточной цитометрии оценивался уровень экспрессии CD31, CD34, CD90, CD117, CD146, CD166, PDGFRB на поверхности клеток.

Результаты

Результаты. Установлено, что мезенхимные клетки сердца от пациентов с дефектом межжелудочковой перегородки статистически значимо отличаются от таковых, полученных от пациентов с тетрадой Фалло, по поверхностным маркерам CD90 и PDGFRB. Уровень экспрессии последнего имеет тенденцию к снижению с возрастом у пациентов с тетрадой Фалло.

Заключение

Заключение. Клетки, полученные из ткани миокарда от пациентов с тетрадой Фалло и от пациентов с дефектом межжелудочковой перегородки, имеют характеристики мезенхимных стволовых клеток. Найденные различия между клетками от двух групп пациентов указывают на то, что патология может влиять на фенотип мезенхимных клеток сердца. По-видимому, стволовые свойства мезенхимных клеток сердца имеют тенденцию к снижению с возрастом.

Objective

Objective. Phenotypic analysis of cardiac mesenchymal cells from patients with a ventricular septal defect and tetralogy of Fallot.

Methods

Methods. The study included cardiac mesenchymal cells from 8 patients with ventricular septal defect and from 18 patients with tetralogy of Fallot who underwent surgery. Using the flow cytometry method, the content of the following antigens on the cell surface was evaluated: CD31, CD34, CD90, CD117, CD146, CD166, PDGFRB.

Results

Results. Cardiac mesenchymal cells from patients with ventricular septal defect are statistically significantly different from patients with tetralogy of Fallot in surface markers CD90 and PDGFRB. The content of a stem cell marker PDGFRB tends to decrease with age in patients with tetralogy of Fallot.

Conclusion

Conclusion. The cells obtained from myocardial tissue from patients with tetralogy of Fallot and from patients with ventricular septal defects have characteristics of mesenchymal stem cells. The differences found between the cells from the two groups of patients indicate that pathology can affect the phenotype of cardiac mesenchymal cells. Apparently, the stem properties of the mesenchymal heart cells tend to decrease with age.

врожденные пороки сердцатетрада Фаллодефект межжелудочковой перегородкимезенхимные клетки сердцаcongenital heart defectstetralogy of Fallotventricular septal defectmesenchymal heart cellsReferencesKarl TR, Stocker C. Tetralogy of Fallot and Its Variants. Pediatric critical care medicine. 2016;17(8 Suppl 1):S330–336.Karl TR, Stocker C. Tetralogy of Fallot and Its Variants. Pediatric critical care medicine. 2016;17(8 Suppl 1):S330–336.Bittle GJ, Morales D, Deatrick KB et al. Stem cell therapy for hypoplastic left heart syndrome: mechanism, clinical application, and future directions. Circ Res. 2018;123(2):288–300.Bittle GJ, Morales D, Deatrick KB et al. Stem cell therapy for hypoplastic left heart syndrome: mechanism, clinical application, and future directions. Circ Res. 2018;123(2):288–300.Ishigami S, Ohtsuki S, Eitoku T et al. Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (cardiac progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial. Circ Res. 2017;120(7):1162–1173.Ishigami S, Ohtsuki S, Eitoku T et al. Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (cardiac progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial. Circ Res. 2017;120(7):1162–1173.Tsilimigras DI, Oikonomou EK, Moris D et al. Stem cell therapy for congenital heart disease: a systematic review. Circulation. 2017;136(24):2373–2385.Tsilimigras DI, Oikonomou EK, Moris D et al. Stem cell therapy for congenital heart disease: a systematic review. Circulation. 2017;136(24):2373–2385.Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol. 2011;50(2):296–303.Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol. 2011;50(2):296–303.Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763–776.Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763–776.Hierlihy AM, Seale P, Lobe CG et al. The postnatal heart contains a myocardial stem cell population. FEBS Lett. 2002;530(1–3):239–243.Hierlihy AM, Seale P, Lobe CG et al. The postnatal heart contains a myocardial stem cell population. FEBS Lett. 2002;530(1–3):239–243.Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9):911–921.Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9):911–921.Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313–12318.Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21):12313–12318.Leite CF, Almeida TR, Lopes CS, Dias da Silva VJ. Multipotent stem cells of the heart-do they have therapeutic promise? Front Physiol. 2015;6:123.Leite CF, Almeida TR, Lopes CS, Dias da Silva VJ. Multipotent stem cells of the heart-do they have therapeutic promise? Front Physiol. 2015;6:123.Chong JJ, Chandrakanthan V, Xaymardan M et al. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell. 2011;9(6):527–540.Chong JJ, Chandrakanthan V, Xaymardan M et al. Adult cardiac-resident MSC-like stem cells with a proepicardial origin. Cell Stem Cell. 2011;9(6):527–540.Sultana N, Zhang L, Yan J et al. Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun. 2015;6:8701.Sultana N, Zhang L, Yan J et al. Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun. 2015;6:8701.Epstein JA. A time to press reset and regenerate cardiac stem cell biology. JAMA Cardiol. 2019;4(2):95–96.Epstein JA. A time to press reset and regenerate cardiac stem cell biology. JAMA Cardiol. 2019;4(2):95–96.Zuppo DA, Tsang M. Fusion heals the brokenhearted. Ann Transl Med. 2018;6(Suppl 1):S21.Zuppo DA, Tsang M. Fusion heals the brokenhearted. Ann Transl Med. 2018;6(Suppl 1):S21.Maliken BD, Kanisicak O, Karch J et al. Gata4- dependent differentiation of c-Kit+–derived endothelial cells underlies artefactual cardiomyocyte regeneration in the heart. Circulation. 2018;138(10):1012–1024.Maliken BD, Kanisicak O, Karch J et al. Gata4- dependent differentiation of c-Kit+–derived endothelial cells underlies artefactual cardiomyocyte regeneration in the heart. Circulation. 2018;138(10):1012–1024.Smits AM, van Vliet P, Metz CH et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc. 2009;4(2):232–243.Smits AM, van Vliet P, Metz CH et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc. 2009;4(2):232–243.Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.Mishra R, Vijayan K, Colletti EJ et al. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation. 2011;123(4):364– 373.Mishra R, Vijayan K, Colletti EJ et al. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation. 2011;123(4):364– 373.Sharma S, Mishra R, Bigham GE et al. A deep proteome analysis identifies the complete secretome as the functional unit of human cardiac progenitor cells. Circ Res. 2017;120(5):816–834.Sharma S, Mishra R, Bigham GE et al. A deep proteome analysis identifies the complete secretome as the functional unit of human cardiac progenitor cells. Circ Res. 2017;120(5):816–834.Traister A, Patel R, Huang A et al. Cardiac regenerative capacity is age- and disease-dependent in childhood heart disease. PLoS One. 2018;13(7):e0200342.Traister A, Patel R, Huang A et al. Cardiac regenerative capacity is age- and disease-dependent in childhood heart disease. PLoS One. 2018;13(7):e0200342.Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 2001;23(6):494–507.Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 2001;23(6):494–507.Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15(4):205– 213.Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15(4):205– 213.Ball SG, Worthington JJ, Canfield A et al. Mesenchymal stromal cells: inhibiting PDGF receptors or depleting fibronectin induces mesodermal progenitors with endothelial potential. Stem Cells. 2014;32(3):694–705.Ball SG, Worthington JJ, Canfield A et al. Mesenchymal stromal cells: inhibiting PDGF receptors or depleting fibronectin induces mesodermal progenitors with endothelial potential. Stem Cells. 2014;32(3):694–705.Ishigami S, Ohtsuki S, Tarui S et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015;116(4):653–664.Ishigami S, Ohtsuki S, Tarui S et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015;116(4):653–664.Sano T, Ousaka D, Goto T et al. Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease. Circ Res. 2018;122(7):994–1005.Sano T, Ousaka D, Goto T et al. Impact of cardiac progenitor cells on heart failure and survival in single ventricle congenital heart disease. Circ Res. 2018;122(7):994–1005.Zwetsloot PP, Vegh AM, Jansen of Lorkeers SJ et al. Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical studies. Circ Res. 2016;118(8):1223–1232.Zwetsloot PP, Vegh AM, Jansen of Lorkeers SJ et al. Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical studies. Circ Res. 2016;118(8):1223–1232.Martin-Rendon E. Meta-analyses of human cellbased cardiac regeneration therapies: what can systematic reviews tell us about cell therapies for ischemic heart disease? Circ Res. 2016;118(8):1264–1272.Martin-Rendon E. Meta-analyses of human cellbased cardiac regeneration therapies: what can systematic reviews tell us about cell therapies for ischemic heart disease? Circ Res. 2016;118(8):1264–1272.Gyöngyösi M, Wojakowski W, Navarese EP et al. Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res. 2016;118(8):1254– 1263.Gyöngyösi M, Wojakowski W, Navarese EP et al. Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res. 2016;118(8):1254– 1263.Zwetsloot PP, Gremmels H, Assmus B et al. Responder definition in clinical stem cell trials in cardiology: will the real responder please stand up? Circ Res. 2016;119(4):514–518.Zwetsloot PP, Gremmels H, Assmus B et al. Responder definition in clinical stem cell trials in cardiology: will the real responder please stand up? Circ Res. 2016;119(4):514–518.

The authors declare that there are no conflicts of interest present.